EUCTR2018-001894-26-FI进行中（未招募）1 期
A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12,120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects must have read, understood, and signed the informed consent form (ICF);
- •Subject must have a body mass index (BMI) = 35 kg/m^2;
- •Male and female subjects must be 65 years of age and older at the Screening/Vaccination visit (Visit 1);
- •Subjects must be non-institutionalized (e.g. not living in rehabilitation centres or old-age homes; living in an elderly community is acceptable) and have no acute or evolving medical problems prior to study participation and no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12120
排除标准
- •According to the Investigator’s opinion, history of an ongoing acute or evolving medical or neuropsychiatric illness (see protocol for definition of 'evolving');
- •Any autoimmune disease other than hypothyroidism on stable replacement therapy or any confirmed or suspected immunosuppressive condition or immunodeficiency;
- •Any history of status asthmaticus or ongoing serious problems with asthma, hospitalization for asthma control, or recurrent asthma episodes requiring medical attention in the last three years;
- •Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization up to blood sampling on Day 21;
- •Administration of any adjuvanted or investigational influenza vaccine within one year prior to randomization or planned administration prior to the completion of the study;
- •Administration of any ‘standard’, non-adjuvanted influenza vaccine within six months prior to randomization and up to completion of the study (see protocol for definition of 'standard');
- •Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or equivalent) per day for more than seven consecutive days or for ten or more days in total, within one month of study vaccine administration; any other cytotoxic or immunosuppressant drug, or any immunoglobulin preparation within three months of vaccination and until the completion of the study;
- •Any significant disorder of coagulation including, but not limited to, treatment with warfarin derivatives or heparin;
- •History of allergy to any of the constituents of the Quadrivalent VLP Influenza Vaccine, any components of the active comparator quadrivalent vaccine, or tobacco;
- •History of anaphylactic allergic reactions to plants or plants components;
- •Use of antihistamines, prophylactic medications against influenza or antiviral treatment, or have a blood transfusion prior to study vaccination (see protocol for applicable time periods);
- •Daily use of large doses of medication for pain control or inflammation;
- •Have a rash, dermatological condition, tattoos, muscle mass at the injection site;
- •Presence of any febrile illness within 24 hours prior to vaccination;
- •Cancer or treatment for cancer within three years prior to study vaccine administration;
- •Subjects with a history of Guillain-Barré Syndrome.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate a plant-derived flu vaccine in adults 65 years of age and older in order to assess efficacy, safety and to see how well it works at generating an immune response.Seasonal influenzaMedDRA version: 20.0 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsEUCTR2018-001894-26-DEMedicago R&D Inc.12,000
已完成
2 期
A Randomized, Active-comparator, Observer-blind, Phase I/II/III Study to Demonstrate the Immunogenicity of a Single Booster Dose of DS-5670a in Adults and Elderly Received a Primary Series of Approved COVID-19 VaccineJPRN-jRCT2071210106Inoguchi Akihiro5,028
进行中（未招募）
1 期
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)Postoperative Nausea and VomitingMedDRA version: 8.1 Level: LLT Classification code 10036238EUCTR2006-001761-42-LTMerck & Co., Inc700
进行中（未招募）
1 期
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)Postoperative Nausea and VomitingClassification code 10036238EUCTR2006-001761-42-ATMerck Sharp & Dohme GesmbH700
进行中（未招募）
不适用
A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects with Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel) - NAEUCTR2010-019001-42-BGTeva Pharmaceutical Works Private Limited Company300